Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1961 1
1963 1
1964 2
1966 1
1967 4
1973 1
1975 3
1976 4
1978 2
1979 3
1980 3
1985 3
1986 2
1988 2
1989 2
1991 4
1992 2
1993 3
1994 2
1995 3
1996 1
1997 3
1998 3
2000 6
2001 9
2002 5
2003 1
2004 4
2005 3
2006 3
2007 17
2008 14
2009 11
2010 15
2011 18
2012 24
2013 19
2014 16
2015 13
2016 32
2017 37
2018 26
2019 21
2020 38
2021 54
2022 59
2023 43
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

493 results

Results by year

Filters applied: . Clear all
Page 1
Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Xiao L, Kadia T, Daver N, Adeoti M, Short NJ, Sasaki K, Wang S, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Montalban Bravo G, Masarova L, Yilmaz M, Jain N, Andreeff M, Jabbour E, Garcia-Manero G, Kornblau S, Ravandi F, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: maiti a. J Clin Oncol. 2021 Sep 1;39(25):2768-2778. doi: 10.1200/JCO.20.03736. Epub 2021 May 27. J Clin Oncol. 2021. PMID: 34043428 Free PMC article. Clinical Trial.
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia.
DiNardo CD, Lachowiez CA, Takahashi K, Loghavi S, Kadia T, Daver N, Xiao L, Adeoti M, Short NJ, Sasaki K, Wang SA, Borthakur G, Issa G, Maiti A, Alvarado Y, Pemmaraju N, Bravo GM, Masarova L, Yilmaz M, Jain N, Andreeff M, Garcia-Manero G, Kornblau S, Ravandi F, Jabbour E, Konopleva MY, Kantarjian HM. DiNardo CD, et al. Among authors: maiti a. Am J Hematol. 2022 Aug;97(8):1035-1043. doi: 10.1002/ajh.26601. Epub 2022 May 30. Am J Hematol. 2022. PMID: 35583199 Free article.
Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax.
Kim K, Maiti A, Loghavi S, Pourebrahim R, Kadia TM, Rausch CR, Furudate K, Daver NG, Alvarado Y, Ohanian M, Sasaki K, Short NJ, Takahashi K, Yilmaz M, Tang G, Ravandi F, Kantarjian HM, DiNardo CD, Konopleva MY. Kim K, et al. Among authors: maiti a. Cancer. 2021 Oct 15;127(20):3772-3781. doi: 10.1002/cncr.33689. Epub 2021 Jul 13. Cancer. 2021. PMID: 34255353 Free PMC article.
Phenytoin toxicity.
Awasthi A, Agrawal N, Chakraborty PP, Maiti A. Awasthi A, et al. Among authors: maiti a. BMJ Case Rep. 2022 Nov 11;15(11):e253250. doi: 10.1136/bcr-2022-253250. BMJ Case Rep. 2022. PMID: 36368739 No abstract available.
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia.
Rausch CR, DiNardo CD, Maiti A, Jammal NJ, Kadia TM, Marx KR, Borthakur G, Savoy JM, Pemmaraju N, DiPippo AJ, Daver NG, Chew SM, Sasaki K, Issa GC, Short NJ, Takahashi K, Ohanian MN, Ning J, Xiao L, Alvarado Y, Kontoyiannis DP, Ravandi F, Kantarjian HM, Konopleva MY. Rausch CR, et al. Among authors: maiti a. Cancer. 2021 Jul 15;127(14):2489-2499. doi: 10.1002/cncr.33508. Epub 2021 Apr 1. Cancer. 2021. PMID: 33793970 Free PMC article.
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment-related mortality.
Maiti A, Qiao W, Sasaki K, Ravandi F, Kadia TM, Jabbour EJ, Daver NG, Borthakur G, Garcia-Manero G, Pierce SA, Montalbano KS, Pemmaraju N, Naqvi K, Ohanian M, Short NJ, Alvarado Y, Takahashi K, Yilmaz M, Jain N, Kornblau SM, Andreeff M, Bose P, Ferrajoli A, Issa GC, Masarova L, Thompson PA, Rausch CR, Ning J, Kantarjian HM, DiNardo CD, Konopleva MY. Maiti A, et al. Am J Hematol. 2021 Mar 1;96(3):282-291. doi: 10.1002/ajh.26061. Epub 2020 Dec 24. Am J Hematol. 2021. PMID: 33264443 Free PMC article.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Senapati J, Urrutia S, Loghavi S, Short NJ, Issa GC, Maiti A, Abbas HA, Daver NG, Pemmaraju N, Pierce S, Chien KS, Sasaki K, Kadia TM, Hammond DE, Borthakur G, Patel K, Ravandi F, Kantarjian HM, Garcia-Manero G, DiNardo CD. Senapati J, et al. Among authors: maiti a. Blood. 2023 Nov 9;142(19):1647-1657. doi: 10.1182/blood.2023020649. Blood. 2023. PMID: 37441846
Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study.
Lachowiez CA, Reville PK, Kantarjian H, Jabbour E, Borthakur G, Daver N, Loghavi S, Furudate K, Xiao L, Pierce S, Short NJ, Maiti A, Yilmaz M, Sasaki K, Takahashi K, Konopleva M, Pemmaraju N, Popat U, Shpall E, Garcia-Manero G, Ravandi F, DiNardo CD, Kadia TM. Lachowiez CA, et al. Among authors: maiti a. Lancet Haematol. 2022 May;9(5):e350-e360. doi: 10.1016/S2352-3026(22)00076-X. Lancet Haematol. 2022. PMID: 35483396 Free PMC article. Clinical Trial.
493 results